ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) is a rare and heterogeneous subtype of SM and few studies on this specific entity have been reported. Sixty two patients with Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-A...
Main Authors: | Gandhi Damaj, Magalie Joris, Olivia Chandesris, Katia Hanssens, Erinn Soucie, Danielle Canioni, Brigitte Kolb, Isabelle Durieu, Emanuel Gyan, Cristina Livideanu, Stephane Chèze, Momar Diouf, Reda Garidi, Sophie Georgin-Lavialle, Vahid Asnafi, Ludovic Lhermitte, Christian Lavigne, David Launay, Michel Arock, Olivier Lortholary, Patrice Dubreuil, Olivier Hermine |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3897447?pdf=render |
Similar Items
-
Clinical potential of midostaurin in advanced systemic mastocytosis
by: Chandesris MO, et al.
Published: (2017-05-01) -
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
by: Magalie Joris, et al.
Published: (2012-01-01) -
Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.
by: Daniela Silva Moura, et al.
Published: (2012-01-01) -
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
by: Daniela Silva Moura, et al.
Published: (2011-01-01) -
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.
by: Fanny Lanternier, et al.
Published: (2008-04-01)